Tumor mutation burden (TMB), programmed cell death ligand 1(PD-L1) expression, and the infiltrations of some vital cell types in tumor immune microenvironments were considered close to response to ICI [13–17], while how they regulated patients with EGFR 20ins mutations responding to ICI were still unclear. The gene discussed is CD274; the disease is neoplasm.